Literature DB >> 2012137

Retrospective survey of urea cycle disorders: Part 1. Clinical and laboratory observations of thirty-two Japanese male patients with ornithine transcarbamylase deficiency.

I Matsuda1, N Nagata, T Matsuura, K Oyanagi, K Tada, K Narisawa, T Kitagawa, T Sakiyama, F Yamashita, M Yoshino.   

Abstract

In a retrospective survey done from 1978-1988 in Japan, 32 male patients with ornithine transcarbamylase (OTC) deficiency were identified. We classified a neonatal and 2 late-onset groups, depending on clinical manifestations and the age at onset; group 1 (0-28 days; N = 10), group 2 (29 days-5 years; N = 13), and group 3 (greater than 5 years; N = 9). Compared to findings in the group 2 patients, there was a higher rate of mortality and a higher incidence of mental retardation in association with a great decrease in enzyme activity in group 1. In group 3, the mortality rate and enzyme activities were similar to those in group 1. However, patients in this group were asymptomatic prior to the first episode. Enzyme activities were measured mostly in autopsy samples. The serum citrulline levels (enzyme product) were highest in this group. Thus, the mutant enzymes were apparently labile with greater activities in vivo than in vitro. Treatments, including a protein-restricted diet, arginine supplementation, and sodium benzoate administration, resulted in a favorable prognosis for survivors with partial enzyme deficiency. We wish to emphasize that the incidence of late onset of this disease is higher than heretofore considered.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2012137     DOI: 10.1002/ajmg.1320380119

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  16 in total

Review 1.  Ornithine carbamoyl transferase deficiency: findings, models and problems.

Authors:  C Bachmann
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Long-term outcome and intervention of urea cycle disorders in Japan.

Authors:  Jun Kido; Kimitoshi Nakamura; Hiroshi Mitsubuchi; Toshihiro Ohura; Masaki Takayanagi; Masafumi Matsuo; Makoto Yoshino; Yosuke Shigematsu; Tohru Yorifuji; Mureo Kasahara; Reiko Horikawa; Fumio Endo
Journal:  J Inherit Metab Dis       Date:  2011-12-14       Impact factor: 4.982

3.  A novel missense mutation in exon 8 of the ornithine transcarbamylase gene in two unrelated male patients with mild ornithine transcarbamylase deficiency.

Authors:  A Hata; T Matsuura; C Setoyama; K Shimada; T Yokoi; I Akaboshi; I Matsuda
Journal:  Hum Genet       Date:  1991-05       Impact factor: 4.132

4.  In vivo nitrogen metabolism in ornithine transcarbamylase deficiency.

Authors:  M Yudkoff; Y Daikhin; I Nissim; A Jawad; J Wilson; M Batshaw
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

5.  Specificity of PCR-SSCP for detection of the mutant ornithine transcarbamylase (OTC) gene in patients with OTC deficiency.

Authors:  R Hoshide; T Matsuura; S Komaki; E Koike; I Ueno; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Identification of two new aberrant splicings in the ornithine carbamoyltransferase (OCT) gene in two patients with early and late onset OCT deficiency.

Authors:  T Matsuura; R Hoshide; S Komaki; K Kiwaki; F Endo; S Nakamura; T Jitosho; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

7.  Prenatal monitoring of ornithine transcarbamoylase deficiency in two families by DNA analysis.

Authors:  T Matsuura; R Hoshide; M Fukushima; T Sakiyama; M Owada; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

8.  Four novel gene mutations in five Japanese male patients with neonatal or late onset OTC deficiency: application of PCR-single-strand conformation polymorphisms for all exons and adjacent introns [corrected].

Authors:  T Matsuura; R Hoshide; C Setoyama; K Shimada; Y Hase; T Yanagawa; M Kajita; I Matsuda
Journal:  Hum Genet       Date:  1993-08       Impact factor: 4.132

9.  Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan.

Authors:  T Uchino; F Endo; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

10.  Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency.

Authors:  S E Raper; J M Wilson; M Yudkoff; M B Robinson; X Ye; M L Batshaw
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.